TAE684 (NVP-TAE684)

Catalog No.S1108

TAE684 (NVP-TAE684) Chemical Structure

Molecular Weight(MW): 614.2

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Size Price Stock Quantity  
USD 160 In stock
USD 290 In stock
USD 770 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) H3122 xenografts harboring the EML4-ALK translocation were treated with control vehicle or the ALK inhibitor, TAE-684, for 2 days; the tumors were excised and lysates were prepared. The TIMM results for the control and treated animals are shown. (B) H3122 cells were treated in the presence or absence of TAE-684 (100 nM) for 6 hours in the presence or absence of the indicated ligands [EGF (50 ng/mL), IGF1 (50 ng/mL), and HGF (50 ng/mL)]. Extracts were probed with the indicated antibodies.

    Cancer Res 2011 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (B) Dosage effects of TAE684 on phospho-Y1604 ALK expression of wild-type, H694R, and E1384K transfectants by Western blot analysis (top panel). Quantitative results of phospho-Y1604 ALK intensity are also (bottom panel).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

  • Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (C) Suppressive effects of TAE684 on H694R- and E1384K-induced tumors in vivo. Photographs and tumor growth curves are shown in the top and bottom panels, respectively (four mice per group).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (A) Dosage effects of TAE684 on H694R- and E1384K-induced cell proliferation measured with WST-1 activity. 

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

Purity & Quality Control

Choose Selective ALK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets
ALK [1]
(Cell-free assay)
3 nM
In vitro

TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NG\C[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LyeWlEPTB;MD6wNFAxPjB|IN88US=> MkLMV2FPT0WU
SF539 NXHKcmkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrkPG5KSzVyPUCuNFAxPTZ2IN88US=> MV\TRW5ITVJ?
DEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLQUW9KSzVyPUCuNFAxQTJ5IN88US=> M2f4WHNCVkeHUh?=
NB1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DuR2lEPTB;MD6wNFE3OiEQvF2= M3PLWXNCVkeHUh?=
SR NV\afXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L0VGlEPTB;MD6wNFI4PyEQvF2= M4nmTnNCVkeHUh?=
KARPAS-299 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG2U3JKSzVyPUCuNFI{QDRizszN NGXOZm9USU6JRWK=
MHH-CALL-2 NEf3XY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LveWlEPTB;MD6wNlk2OiEQvF2= M1fLfXNCVkeHUh?=
SU-DHL-1 NV30U|g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX1TWM2OD1yLkC0PFY2KM7:TR?= NWTPTHNyW0GQR1XS
A4-Fuk NHnITYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD6N3hKSzVyPUCuNFU2PjVizszN MUXTRW5ITVJ?
EW-1 M1qxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i1WWlEPTB;MD6xNFI2PiEQvF2= MoLOV2FPT0WU
NOS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vSW2lEPTB;MD6xNFI6PCEQvF2= Mmj4V2FPT0WU
EW-16 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{mz[GlEPTB;MD6xNFU3QCEQvF2= M4rFUXNCVkeHUh?=
TE-11 NFG1bmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zaNWlEPTB;MD6xOlA6PiEQvF2= M4\1TXNCVkeHUh?=
SW982 NF;BWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fhd2lEPTB;MD6xOlQ4QCEQvF2= MXzTRW5ITVJ?
LAN-6 M4XFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELEVJdKSzVyPUCuNVc1PDNizszN M1jzdXNCVkeHUh?=
MZ1-PC M1H5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPrdIxwUUN3ME2wMlE4QDN3IN88US=> M1H1fnNCVkeHUh?=
KS-1 NEOzTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XFc2lEPTB;MD6xPVM1OyEQvF2= NETSOYRUSU6JRWK=
PSN1 NGHqS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrPTWM2OD1yLkG5OlMyKM7:TR?= NHu1[WNUSU6JRWK=
LC-2-ad MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3LVFBKSzVyPUCuNVk3QTJizszN NGTzbnBUSU6JRWK=
COLO-320-HSR MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3POWWlEPTB;MD6xPVc4PiEQvF2= M4DBSnNCVkeHUh?=
OPM-2 M4HtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP3UYVVUUN3ME2wMlIzPjZ7IN88US=> NW\MVnFlW0GQR1XS
SK-NEP-1 M3zUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K3cWlEPTB;MD6yN|UzPCEQvF2= NWHrW3pTW0GQR1XS
ALL-PO NWHDTHZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\Z[YhTUUN3ME2wMlI1PTJ2IN88US=> M3jmcXNCVkeHUh?=
CMK M4fJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HOV2lEPTB;MD6yOVU{KM7:TR?= MlTaV2FPT0WU
NCI-H1648 NFr1WYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjBSIdKSzVyPUCuNlc5PTVizszN MWrTRW5ITVJ?
SIG-M5 MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTWTWM2OD1yLkK5NVU6KM7:TR?= NVu4V2VpW0GQR1XS
TGBC24TKB M1\LXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfPTWM2OD1yLkOwNlE5KM7:TR?= MoDxV2FPT0WU
DOHH-2 NXX2bZp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwM{GyNFQh|ryP MlfoV2FPT0WU
NB69 MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLETWM2OD1yLkOxO|g4KM7:TR?= MUPTRW5ITVJ?
MFH-ino MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SxO2lEPTB;MD6zNlUzOyEQvF2= NULId5RCW0GQR1XS
KP-N-RT-BM-1 NWfYflZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\STWM2OD1yLkOzNVI{KM7:TR?= NXjZVFZHW0GQR1XS
MONO-MAC-6 M3jZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\IXVhKSzVyPUCuN|MzQTFizszN M1j2W3NCVkeHUh?=
ATN-1 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDwTWM2OD1yLkOzN|A{KM7:TR?= Mly1V2FPT0WU
NTERA-S-cl-D1 NWHVO|BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i5fWlEPTB;MD6zN|M6PiEQvF2= NEnPTVVUSU6JRWK=
L-540 NXLHeWd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELkSWtKSzVyPUCuN|Y6QDhizszN MljkV2FPT0WU
GB-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnsTWM2OD1yLkO4PFY4KM7:TR?= MVjTRW5ITVJ?
MV-4-11 NX:5U5FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvOTWM2OD1yLkO5OFQ3KM7:TR?= NEnvUGdUSU6JRWK=
KG-1 NYrCOVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L3dmlEPTB;MD6zPVU3OSEQvF2= NWrRdFB{W0GQR1XS
OVCAR-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwNEC1Olkh|ryP NV7Q[oxQW0GQR1XS
NEC8 NV\BcHNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu1NmE2UUN3ME2wMlQyOjl{IN88US=> NFuwVW9USU6JRWK=
SK-MM-2 M2nFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTnWIdJUUN3ME2wMlQyPjB7IN88US=> NIeyXllUSU6JRWK=
TE-8 M1[5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwNEK4PEDPxE1? NYDUV|djW0GQR1XS
697 NFvpV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrqVnlKSzVyPUCuOFMzOTVizszN NHfVSYFUSU6JRWK=
NB14 MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETkbW1KSzVyPUCuOFM5OjZizszN NWj5TllPW0GQR1XS
GDM-1 NFrmeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7zWmdsUUN3ME2wMlQ4OTF4IN88US=> M3jJRXNCVkeHUh?=
HUTU-80 NFzxOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwNEezO|Uh|ryP MVLTRW5ITVJ?
HL-60 NH7jS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\ZT4FKSzVyPUCuOFgyPDJizszN MWDTRW5ITVJ?
OCI-AML2 M4XmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT3[WVIUUN3ME2wMlQ5OzJ6IN88US=> MkDUV2FPT0WU
ML-2 MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm2TWM2OD1yLkS5NFMyKM7:TR?= MYXTRW5ITVJ?
ES4 NUHLZ|NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2wW|NKSzVyPUCuOFkyODlizszN NWracm4xW0GQR1XS
NCI-H747 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrSUIVpUUN3ME2wMlQ6QDlizszN NEnBe3VUSU6JRWK=
RL95-2 MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPHNW5KSzVyPUCuOVAyOTJizszN MWXTRW5ITVJ?
TE-15 NHfM[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HDNmlEPTB;MD61NVEzPCEQvF2= MW\TRW5ITVJ?
TE-12 NUjQbndyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwNUOzOFkh|ryP MkPlV2FPT0WU
LB1047-RCC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrpTWM2OD1yLkW0OVQ6KM7:TR?= NYDkcotZW0GQR1XS
LB831-BLC MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXYbVhTUUN3ME2wMlU2ODJ|IN88US=> M2fheXNCVkeHUh?=
NCI-H1355 NGe4fGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrHRVJXUUN3ME2wMlU2OTh2IN88US=> MorRV2FPT0WU
CTV-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XMT2lEPTB;MD61OVYzPCEQvF2= MojEV2FPT0WU
RXF393 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwNUW3PVQh|ryP M2rBPXNCVkeHUh?=
SW872 NYDZR|BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fNN2lEPTB;MD61OlczPCEQvF2= M1n2RnNCVkeHUh?=
MPP-89 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPrOIxKSzVyPUCuOVc5QDRizszN MnGxV2FPT0WU
RPMI-8226 NFHC[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y4c2lEPTB;MD62N|UzPiEQvF2= M2KyXXNCVkeHUh?=
LS-1034 NF\E[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XSXmlEPTB;MD62N|U5KM7:TR?= MojHV2FPT0WU
SJSA-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLZVZlNUUN3ME2wMlY{PzJ3IN88US=> NYHrUnhEW0GQR1XS
HOP-62 NGDqWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL4T2pKSzVyPUCuOlUxOzNizszN M{jOXXNCVkeHUh?=
KGN M2XHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TISWlEPTB;MD62OlE3QCEQvF2= M365TXNCVkeHUh?=
D-336MG MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW0OI5KSzVyPUCuOlYyPjlizszN NH\0VoJUSU6JRWK=
LS-411N MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELxclhKSzVyPUCuOlc1PjJizszN NVTodYQ6W0GQR1XS
TE-1 M3jIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XWZWlEPTB;MD62PVA4PCEQvF2= MUjTRW5ITVJ?
LB996-RCC M1LUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHRTWM2OD1yLk[5N|g6KM7:TR?= MX;TRW5ITVJ?
TE-10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf3b21CUUN3ME2wMlcyPDl4IN88US=> MnLnV2FPT0WU
NCI-SNU-16 M4Gz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS4OYdKSzVyPUCuO|I3PjRizszN MlrnV2FPT0WU
ES8 M3f0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwN{S5O|Uh|ryP NFmwcZNUSU6JRWK=
COLO-800 NWLSUGpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzPc4dKSzVyPUCuO|Y3QTVizszN M4LzZ3NCVkeHUh?=
ES6 NYO4PHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELE[oFKSzVyPUCuO|c2PTlizszN MYLTRW5ITVJ?
L-363 NYnz[4t1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXNbHh6UUN3ME2wMlgzOzd3IN88US=> MnL6V2FPT0WU
NMC-G1 NFnlenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqzO5JKSzVyPUCuPFMzOzNizszN MWLTRW5ITVJ?
LU-134-A NXPQfZVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PJXWlEPTB;MD64N|kyOiEQvF2= MmO5V2FPT0WU
SF268 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnLZmx4UUN3ME2wMlg1ODR{IN88US=> NHzLUnhUSU6JRWK=
KARPAS-45 NHPme5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjTTZFYUUN3ME2wMlg1OjZ|IN88US=> NEHJW4NUSU6JRWK=
TGW NYDweIJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TDRWlEPTB;MD64OVg3OyEQvF2= NF3TNHFUSU6JRWK=
CHP-126 NHryZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwOEW5OVch|ryP NUftWpJ2W0GQR1XS
MOLT-16 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwOEe1PFkh|ryP Mo\hV2FPT0WU
LB771-HNC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[3TWM2OD1yLki5O|U4KM7:TR?= MlH0V2FPT0WU
NALM-6 NEi3VpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLVXYpKSzVyPUCuPVA4OzlizszN M4T4fnNCVkeHUh?=
GCIY MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrvTWM2OD1yLkm1OVI3KM7:TR?= NGn4WXJUSU6JRWK=
IST-MES1 M{f5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzYTWM2OD1yLkm4PFI1KM7:TR?= M3vXWHNCVkeHUh?=
LB2241-RCC NX25ZY8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXUR4RKSzVyPUCuPVg5PCEQvF2= MV\TRW5ITVJ?
BL-70 M{jSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LjRmlEPTB;MD65PVU{PSEQvF2= MkXEV2FPT0WU
NB17 M1\zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzlbpdKSzVyPUGuNFA3OzlizszN M1;WeXNCVkeHUh?=
LXF-289 M1ruc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnoZY1PUUN3ME2xMlA{ODd4IN88US=> MYjTRW5ITVJ?
TK10 NUn4UJVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vwWGlEPTB;MT6wOVA3OyEQvF2= M1ruTHNCVkeHUh?=
K5 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwME[yO|Qh|ryP M1LuN3NCVkeHUh?=
NCI-H716 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwMEeyOVkh|ryP M37HSHNCVkeHUh?=
HCE-T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW1TWM2OD1zLkC4PFE6KM7:TR?= MUXTRW5ITVJ?
GI-1 NUG3cnVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[yblZ2UUN3ME2xMlA6Pzl6IN88US=> MVrTRW5ITVJ?
KARPAS-422 M1zKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfCTWM2OD1zLkGwNFIzKM7:TR?= NVO3ZmFIW0GQR1XS
TE-9 NVfVdFg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;nfnNKSzVyPUGuNVE{OjhizszN NWXjXopwW0GQR1XS
SF126 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHjTWM2OD1zLkGxOVY5KM7:TR?= NG[ydIZUSU6JRWK=
BB30-HNC NH;VSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHk[otKSzVyPUGuNVMyOTJizszN MlLZV2FPT0WU
NCI-H1304 NWjSXVRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6xdmpPUUN3ME2xMlE{OzN6IN88US=> MnO5V2FPT0WU
HEL NYDwPWtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17KcGlEPTB;MT6xOFg6PSEQvF2= NHzhXItUSU6JRWK=
HAL-01 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrYcHpKSzVyPUGuNVUzQDNizszN M{D4[XNCVkeHUh?=
SK-LMS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELxRpFKSzVyPUGuNVU6PzRizszN MofxV2FPT0WU
SW954 M4rnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHzTWM2OD1zLkG5OVY4KM7:TR?= NEjufWtUSU6JRWK=
D-283MED NXXFS|FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLyRm5KSzVyPUGuNlI{PzlizszN NWHJWI11W0GQR1XS
NCI-H1882 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwMkO4PUDPxE1? M33XTHNCVkeHUh?=
GI-ME-N M4TkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfsXINZUUN3ME2xMlI2OjB6IN88US=> MYTTRW5ITVJ?
SK-PN-DW MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjjTWM2OD1zLkK2N|Q5KM7:TR?= NYq0VW13W0GQR1XS
C2BBe1 NV\Tb|BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMkmxNVch|ryP NEDnVWNUSU6JRWK=
A704 M4fpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jnZWlEPTB;MT6zNlY5QSEQvF2= MYTTRW5ITVJ?
KALS-1 M3rmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi5eGRKSzVyPUGuN|QxQCEQvF2= NWnKWHVLW0GQR1XS
ETK-1 M4TrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\KbYZIUUN3ME2xMlM1PDh7IN88US=> NUH6XIdOW0GQR1XS
LB647-SCLC M4\xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomwTWM2OD1zLkO0PVg3KM7:TR?= NXTTeWN3W0GQR1XS
OCUB-M MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHjTWM2OD1zLkO2NVQ{KM7:TR?= NWPESI9UW0GQR1XS
NCI-H720 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDSNlhzUUN3ME2xMlM3Ozd6IN88US=> MlLQV2FPT0WU
NB13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTqOXVKSzVyPUGuN|czQTNizszN MVPTRW5ITVJ?
GR-ST M1XOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\aZ4ZJUUN3ME2xMlM5PzV5IN88US=> MWDTRW5ITVJ?
DU-4475 MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKxTWM2OD1zLkS1PFU{KM7:TR?= MXLTRW5ITVJ?
HCC2157 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwNE[2OVkh|ryP M1HxUHNCVkeHUh?=
RKO M3rRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H4RmlEPTB;MT60PVkzOiEQvF2= MkToV2FPT0WU
LS-123 NHjEN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P6bWlEPTB;MT61NVU6PCEQvF2= M3TxZXNCVkeHUh?=
NCI-H69 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwNUW4NVEh|ryP M2jIV3NCVkeHUh?=
SW962 NFjGemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwNU[xN{DPxE1? NWr5WVl2W0GQR1XS
PF-382 NEK1VGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfQfGhKSzVyPUGuOVY6PiEQvF2= MofFV2FPT0WU
A101D NGGyO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;2TWM2OD1zLkW3NVE{KM7:TR?= M{jvb3NCVkeHUh?=
NB10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoflTWM2OD1zLkW3N|kzKM7:TR?= NEXodXRUSU6JRWK=
NB5 NWflTmV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TCPWlEPTB;MT61PFQ4PiEQvF2= M4XyfnNCVkeHUh?=
HCE-4 M36zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HtSGlEPTB;MT62NFg2KM7:TR?= NVeyOmc5W0GQR1XS
HT-144 NEexNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFwNkOxPUDPxE1? Mly1V2FPT0WU
NCI-H524 NU\leZhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\PdndKSzVyPUGuOlQ{ODdizszN NY\NcoYxW0GQR1XS
NKM-1 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPhVpRKSzVyPUGuOlg3PiEQvF2= NVjhXY9PW0GQR1XS
KURAMOCHI M3fGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe1NWRKSzVyPUGuOlk2PzNizszN NIXXcWlUSU6JRWK=
NCI-H187 M1r6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPQTWM2OD1zLkewNFM3KM7:TR?= NIjpdVVUSU6JRWK=
U-266 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3UTWM2OD1zLkezPFQzKM7:TR?= MU\TRW5ITVJ?
BL-41 M3;6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDuV4NKSzVyPUGuO|YzPzJizszN NV3JU|FKW0GQR1XS
SK-N-DZ NXHXb2VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX34TI1KUUN3ME2xMlc5OzB7IN88US=> MWLTRW5ITVJ?
Daudi NFfZblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL1bI5KSzVyPUGuO|g6PjdizszN NVLlS3lXW0GQR1XS
CPC-N M1j1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHFTWM2OD1zLki1NFk3KM7:TR?= NWfhOWFSW0GQR1XS
EM-2 NV3od|NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP5TXZRUUN3ME2xMlg2OSEQvF2= M2rNUnNCVkeHUh?=
HCC1187 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZZWlEPTB;MT64OlI1OSEQvF2= MWTTRW5ITVJ?
LP-1 NH3rZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13yXGlEPTB;MT64O|E1OyEQvF2= M1nOfXNCVkeHUh?=
CAS-1 M1TSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nD[WlEPTB;MT65PFI6QSEQvF2= NILIeXNUSU6JRWK=
NB7 NGHUPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHoWWRKSzVyPUKuNFA2PTVizszN MmPMV2FPT0WU
VA-ES-BJ NEflTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWizWFVnUUN3ME2yMlAyPTF|IN88US=> MULTRW5ITVJ?
SNU-C2B NEfJV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\FTWM2OD1{LkCzN|UyKM7:TR?= MmPrV2FPT0WU
LOXIMVI Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TqdGlEPTB;Mj6wOlc5PiEQvF2= M4Pyc3NCVkeHUh?=
NCI-H1581 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3nTWM2OD1{LkGxOVU6KM7:TR?= MWDTRW5ITVJ?
IST-SL2 NXrLXmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfQTWM2OD1{LkGyOFQ2KM7:TR?= MoDnV2FPT0WU
NOMO-1 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S4fWlEPTB;Mj6xO|Y5OyEQvF2= MkDVV2FPT0WU
TE-6 NVPmfIFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrmc5lKSzVyPUKuNVkxPSEQvF2= MX3TRW5ITVJ?
NCI-H526 NFHaVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWiyXINxUUN3ME2yMlE6OTRzIN88US=> Ml3uV2FPT0WU
MSTO-211H NUDOeFBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLTTWM2OD1{LkKwNFQyKM7:TR?= MoTOV2FPT0WU
LS-513 NVfVOnJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33CUGlEPTB;Mj6yNlI3QSEQvF2= MmizV2FPT0WU
NCI-SNU-1 NGnGToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLPTWM2OD1{LkOzNlU3KM7:TR?= NYXXUpA2W0GQR1XS
BB65-RCC MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzKTWM2OD1{LkO3OFk{KM7:TR?= MWfTRW5ITVJ?
GT3TKB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSwTWM2OD1{LkO5PVczKM7:TR?= MlTrV2FPT0WU
OS-RC-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e3ZWlEPTB;Mj60NlM1OSEQvF2= NFj2RVFUSU6JRWK=
NCI-H2126 NInlcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXZTWM2OD1{LkSzOlc1KM7:TR?= MnnUV2FPT0WU
SK-UT-1 NEX5doFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwNEe0Olch|ryP M2\QXnNCVkeHUh?=
DMS-114 M4P6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG4ToFKSzVyPUKuOlE2OjRizszN NX3Fd|YyW0GQR1XS
ONS-76 M3Pqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInzdYtKSzVyPUKuOlM3PDFizszN M3PXOXNCVkeHUh?=
8-MG-BA NHfEepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHhTXk5UUN3ME2yMlY2PDF2IN88US=> MkD4V2FPT0WU
BOKU MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX5RZZJUUN3ME2yMlczPzZ2IN88US=> NInWN2RUSU6JRWK=
LAMA-84 NEHrbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\BR4YzUUN3ME2yMlc6QTF{IN88US=> M4nLenNCVkeHUh?=
ES1 NHTCW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLKTWM2OD1{LkixPFA1KM7:TR?= NWrsPIFiW0GQR1XS
NCI-H1395 NXTkSXhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjSfoFKSzVyPUKuPFIxOTJizszN M{PDVHNCVkeHUh?=
A388 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT1XGZKSzVyPUKuPVYyPyEQvF2= NGLLV4NUSU6JRWK=
NCCIT Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XafGlEPTB;Mz6wPFg3OiEQvF2= NFe0O29USU6JRWK=
HD-MY-Z M1jvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TIbmlEPTB;Mz6xN|IxOyEQvF2= Mnn1V2FPT0WU
NCI-H510A M17Oc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDPRohKSzVyPUOuNVg6PDNizszN NYjBNoYxW0GQR1XS
NCI-N87 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDjd3h5UUN3ME2zMlIxODJizszN NWPROFQ2W0GQR1XS
SCLC-21H MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\jTWM2OD1|LkK2PFU6KM7:TR?= NHjD[2FUSU6JRWK=
SH-4 NV3Xb2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[2UFhiUUN3ME2zMlI5Pzl5IN88US=> MnLtV2FPT0WU
QIMR-WIL M2LoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjLVVhKSzVyPUOuN|I5PDlizszN NGnzRWZUSU6JRWK=
KM12 NGjY[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HyeGlEPTB;Mz6zN|U1PCEQvF2= NIDCPGlUSU6JRWK=
ST486 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjSUG5bUUN3ME2zMlU{QDh|IN88US=> MULTRW5ITVJ?
HC-1 NV;hXlE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq2TZQ2UUN3ME2zMlYzODJ6IN88US=> MkPlV2FPT0WU
BV-173 M13GN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnZTWM2OD1|Lk[0NFg5KM7:TR?= NXHjS|llW0GQR1XS
EW-24 NFvYOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PBV2lEPTB;Mz62OlQ{PCEQvF2= M{TU[HNCVkeHUh?=
LU-65 NH3FSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f5dWlEPTB;Mz62PFcyKM7:TR?= NWT6OoNYW0GQR1XS
ECC4 NEC5SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7IXmR1UUN3ME2zMlc4PTZizszN M33wcXNCVkeHUh?=
ARH-77 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPQ[oRKSzVyPUSuNVExPjdizszN MorjV2FPT0WU
BC-3 NES5R41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf2TWM2OD12LkGzNFY5KM7:TR?= NEX1VGxUSU6JRWK=
SNB75 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPrSWZKSzVyPUSuNlYyQSEQvF2= NFrEOphUSU6JRWK=
MEG-01 NHXFWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u4TGlEPTB;ND6yO|QyQSEQvF2= MoXsV2FPT0WU
NCI-H1417 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDjTWM2OD12LkK4OFQ{KM7:TR?= MV\TRW5ITVJ?
MDA-MB-134-VI NUX1TpNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn5TWM2OD12LkOwOlAyKM7:TR?= MXvTRW5ITVJ?
Becker MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3ic4pKSzVyPUSuOFc{OzZizszN MX\TRW5ITVJ?
DMS-153 MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTRwNk[0O|Uh|ryP MWjTRW5ITVJ?
TGBC1TKB Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXJTWM2OD12Lk[4OVE2KM7:TR?= NIDwNY1USU6JRWK=
EW-3 NXGzXXZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn1XYJQUUN3ME20Mlc3OjR6IN88US=> MnLmV2FPT0WU
KE-37 NH62fnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HPOmlEPTB;ND64OlE6PiEQvF2= NUj2ZYk5W0GQR1XS
NCI-H23 NYTYN4pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQd2lEPTB;ND64O|IzPyEQvF2= Mk[4V2FPT0WU
MC116 NUHoepFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nxZmlEPTB;ND65OFEzPiEQvF2= NEjBcGRUSU6JRWK=
NH-12 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknBTWM2OD12Lkm2OFM6KM7:TR?= MkW0V2FPT0WU
CTB-1 NWDMbItNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XHUmlEPTB;ND65O|czOSEQvF2= NVrYbpBOW0GQR1XS
KM-H2 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHGW2VmUUN3ME21MlA2OzJ|IN88US=> NFT3cZlUSU6JRWK=
MOLT-4 M1\nTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PpdmlEPTB;NT6xNVg{KM7:TR?= MVXTRW5ITVJ?
NCI-H2141 MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjae2VbUUN3ME21MlE1OjZ6IN88US=> MVTTRW5ITVJ?
EB-3 NWXxeFlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXwUY1sUUN3ME21MlE4PTB2IN88US=> NIT0PHBUSU6JRWK=
NCI-H1522 M2LoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL6NZloUUN3ME21MlI3OzJ{IN88US=> MVrTRW5ITVJ?
MRK-nu-1 NV7jcI9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXOdWVKSzVyPUWuOFM3OzNizszN NGmyV|lUSU6JRWK=
no-11 M2XOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy2[VFKSzVyPUWuOFcxQDdizszN NGqxO4FUSU6JRWK=
CESS NHftSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHITWM2OD13LkW4NFM1KM7:TR?= M37iNnNCVkeHUh?=
KMOE-2 MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjCPHVzUUN3ME21MlU5PjV7IN88US=> MWDTRW5ITVJ?
REH MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXVTWM2OD14LkK1OlE5KM7:TR?= NVTz[mJIW0GQR1XS
KU812 NFPCVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLDTWM2OD14LkSyO|kyKM7:TR?= MkeyV2FPT0WU
SK-N-FI M3\uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDpTWM2OD14Lk[wOlc1KM7:TR?= MmjSV2FPT0WU
MMAC-SF NV;0WppRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG0[VlKSzVyPUeuNFY1QTJizszN MnHJV2FPT0WU
RCC10RGB Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX73OWxCUUN3ME23MlIzQTd5IN88US=> MXvTRW5ITVJ?
NCI-H322M MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\QTWM2OD15LkOzN|M2KM7:TR?= MlzMV2FPT0WU
NB6 NH3VN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf1cIdKSzVyPUeuOVQ5QTlizszN MoLkV2FPT0WU
MN-60 M4[zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjETWM2OD15Lk[5NlE2KM7:TR?= NWHOTop2W0GQR1XS
NCI-H1092 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\RTWM2OD16LkCxO|M1KM7:TR?= MlKzV2FPT0WU
EKVX MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj2TWM2OD16LkS3NFY3KM7:TR?= MmnrV2FPT0WU
D-263MG NIjTW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\USY1KSzVyPUiuOVU{QTZizszN M4XqR3NCVkeHUh?=
NCI-H209 NGPBOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLMc4c5UUN3ME24MlY1ODB4IN88US=> MlrsV2FPT0WU
IST-SL1 Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvZZWR3UUN3ME24Mlg6QDl{IN88US=> M3noUXNCVkeHUh?=
ACN M4CwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[2cppKSzVyPUmuNVkyPTdizszN M3TET3NCVkeHUh?=
MHH-PREB-1 NWroWVRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTlwMkGyNVkh|ryP MVHTRW5ITVJ?
EW-11 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTlwNkWzPVYh|ryP NVP4N2VGW0GQR1XS
KASUMI-1 NFTMS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnjeZBmUUN3ME25Mlc5PzdizszN NHfYcmlUSU6JRWK=
KINGS-1 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fGTGlEPTB;MUCuNlM1PyEQvF2= NV;nd5JSW0GQR1XS
EVSA-T MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PIXmlEPTB;MUCuN|E6OiEQvF2= M{DHb3NCVkeHUh?=
DSH1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmxWZZzUUN3ME2xNE4{QTd{IN88US=> MnPrV2FPT0WU
COLO-824 NYrY[ZplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TKSmlEPTB;MUCuPFY3QSEQvF2= MX;TRW5ITVJ?
K052 M4DTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFyLkmzNlIh|ryP NGTuPWpUSU6JRWK=
SK-MEL-2 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjHR|NKSzVyPUGwMlk6OzlizszN NHm2ZohUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

Protocol

Kinase Assay
+ Expand

In vitro Enzyme Assays.:

All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.
Cell Research
+ Expand
  • Cell lines: Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
  • Concentrations: 1 nM-10 μM
  • Incubation Time: 2–3 days
  • Method: Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
  • Formulation: Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
  • Dosages: 1, 3, and 10 mg/kg
  • Administration: Once daily by oral gavage for 3 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (4.88 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 4 10 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Related ALK Products

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID